Harrow, Inc. Accounts Payable and Other Accrued Liabilities
Harrow, Inc. (HROW) had Accounts Payable and Other Accrued Liabilities of $224.00 thousand as of 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndOtherAccruedLiabilities · last filed 2021-03-08
- 2020-12-31: Accounts Payable and Other Accrued Liabilities $224.00K.
- 2019-12-31: Accounts Payable and Other Accrued Liabilities $371.00K.
- 2018-12-31: Accounts Payable and Other Accrued Liabilities $245.00K.
- 2017-12-31: Accounts Payable and Other Accrued Liabilities $108.00K.
| Period end | Accounts Payable and Other Accrued Liabilities |
|---|---|
| 2020-12-31 | $224.00K 10-K · filed 2021-03-08 |
| 2019-12-31 | $371.00K 10-K · filed 2021-03-08 |
| 2018-12-31 | $245.00K 10-K · filed 2020-03-13 |
| 2017-12-31 | $108.00K 10-K · filed 2019-03-12 |
| 2013-09-30 | $55.78K 10-Q · filed 2013-11-06 |
| 2013-06-30 | $55.78K 10-Q · filed 2013-08-14 |
| 2013-03-31 | $55.78K 10-Q · filed 2013-05-08 |
| 2012-12-31 | $55.78K 10-Q · filed 2013-11-06 |
| 2012-09-30 | $55.78K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $55.78K 10-Q · filed 2012-08-14 |
| 2012-03-31 | $55.78K 10-Q · filed 2012-05-10 |
| 2011-12-31 | $55.78K 10-K · filed 2013-03-18 |
| 2011-09-30 | $111.87K 10-Q · filed 2012-02-23 |
| 2011-06-30 | $111.87K 10-Q · filed 2012-02-23 |
| 2010-12-31 | $111.87K 10-Q · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |